Crispr Therapeutics: Why AI Giant Anthropic's Discovery Has Rocked Gene Editing

CRISPR Therapeutics AG remains a long-term Buy, anchored by Casgevy's success and management’s execution in ex vivo gene ...
Seeking Alpha

Gene editing stocks fall after Anthropic’s CRISPR-like discovery

Gene editing companies traded lower on Wednesday after Anthropic (ANTHRO) announced that its AI model Claude has “autonomously discovered” a new enzyme system similar to the gene-editing tool CRISPR.

Claude Discovers New CRISPR-like Enzyme System—First Achievement from Anthropic's New Life Sciences Lab

On September 23, 2026, Anthropic announced that its newly established life sciences research group and laboratory had ...
Nature

CRISPR-Cas9 genome editing articles from across Nature Portfolio

CRISPR-Cas9 genome editing exploits the CRISPR-Cas system to modify a genome in a targeted manner. Guided by RNA, the Cas9 endonuclease breaks DNA at a target sequence. Imprecise repair of the double ...